Novo Nordisk, type 2 diabetes
Novo Nordisk faces competition from Eli Lilly in new therapeutic areas. Read why I rate NONOF stock as a hold.
As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...
Wylie said: "Ozempic (semaglutide) is a medication licensed for the management of type 2 diabetes. While it has shown ...
On Monday, Novo Nordisk A/S (NYSE:NVO) released the headline results from the SOUL Phase 3 cardiovascular outcomes trial.
A study found that prescriptions for GIP/GLP-1 RA drugs may reduce opioid overdose and alcohol intoxication rates in patients ...
On September 5, 2022, the China National Intellectual Property Association (China’s patent administrative office, hereinafter ...
In a huge new statistical analysis, researchers have found more evidence than ever that drugs like Ozempic can help curb ...
Research published in the journal Addiction indicates that GLP-1 drugs like Ozempic may play a crucial role in reducing ...
We recently compiled a list of the 10 Most Promising Future Stocks According to Analysts. In this article, we are going to ...
Novo Nordisk faces growth deceleration but shows promise. Learn more about NVO stock and why its risk/reward profile may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback